<DOC>
	<DOCNO>NCT01041092</DOCNO>
	<brief_summary>Primary objective : To assess efficacy add raloxifene adjunct antipsychotic treatment improve negative symptom schizophrenia postmenopausal woman . This double-blind , randomize , placebo-controlled study raloxifene adjuvant treatment antipsychotic treatment . Treatment period 12 week . The primary result obtain woman treat 60 mg raloxifene compare treat placebo show great improvement psychotic symptom . The investigator also find improved response aspects social function neuropsychological functioning .</brief_summary>
	<brief_title>Double Blind , Placebo-controlled Study Raloxifene Negative Symptoms Schizophrenia Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Raloxifene Hydrochloride</mesh_term>
	<criteria>Diagnosis schizophrenia ( DSMIV criterion ) Postmenopausal patient . Postmenopause define period one year spontaneous amenorrhea serum follicle stimulate hormone ( FSH ) level &gt; 20IU/L . Stable dos current antipsychotic medication least month prior study initiation . Presence significant negative symptom ( defined one negative symptom score great 4 PANSS scale ) ( Kay 1987 ) Patients give write informed consent participate study . Patients substance abuse/dependence diagnosis previous six month . Mental retardation . Endocrine abnormality , acute chronic liver disease , impaired kidney function . History thromboembolism , breast cancer , abnormal uterine bleeding , history cerebrovascular accident . Patients take hormone replacement therapy . Patients take mood stabilizer medication discontinue .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>